✦ LIBER ✦

Vitamin D repletion and aromatase inhibitor-related bone loss in women non treated with bisphosphonates

✍ Scribed by D. Prieto-Alhambra; S. Servitja; M.K. Javaid; M.J. Pena; L. Garrigos; N.K. Arden; C. Cooper; I. Tusquets; A. Diez-Perez; X. Nogues

Book ID: 116324737
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 60 KB
Volume: 48
Category: Article
ISSN: 8756-3282
DOI: 10.1016/j.bone.2011.03.617

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidance for the prevention of bone loss

Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

✍ R. Rizzoli, J. J. Body, A. De Censi, J. Y. Reginster, P. Piscitelli, M. L. Brand 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 252 KB

Erratum to: Guidance for the prevention

Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper

✍ R. Rizzoli, J. J. Body, A. DeCensi, J. Y. Reginster, P. Piscitelli, M. L. Brandi 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 54 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the